162 related articles for article (PubMed ID: 25715243)
21. Current medical management of hereditary angioedema: follow-up survey of US physicians.
Riedl MA; Banerji A; Gower R
J Allergy Clin Immunol Pract; 2015; 3(2):220-7. PubMed ID: 25609328
[TBL] [Abstract][Full Text] [Related]
22. Treatment response after repeated administration of C1 esterase inhibitor for successive acute hereditary angioedema attacks.
Craig TJ; Bewtra AK; Hurewitz D; Levy R; Janss G; Jacobson KW; Packer F; Bernstein JA; Rojavin MA; Machnig T; Keinecke HO; Wasserman RL
Allergy Asthma Proc; 2012; 33(4):354-61. PubMed ID: 22856636
[TBL] [Abstract][Full Text] [Related]
23. The hereditary angioedema burden of illness study in Europe (HAE-BOIS-Europe): background and methodology.
Bygum A; Aygören-Pürsün E; Caballero T; Beusterien K; Gholizadeh S; Musingarimi P; Wait S; Boysen H
BMC Dermatol; 2012 Apr; 12():4. PubMed ID: 22536794
[TBL] [Abstract][Full Text] [Related]
24. Challenges of C1-inhibitor concentrate self-administration.
Boysen HB; Bouillet L; Aygören-Pürsün E
Int Arch Allergy Immunol; 2013; 161 Suppl 1():21-5. PubMed ID: 23689241
[TBL] [Abstract][Full Text] [Related]
25. Recombinant human C1 esterase inhibitor for the treatment of hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE).
Sabharwal G; Craig T
Expert Rev Clin Immunol; 2015 Mar; 11(3):319-27. PubMed ID: 25669442
[TBL] [Abstract][Full Text] [Related]
26. HAE update: epidemiology and burden of disease.
Bernstein JA
Allergy Asthma Proc; 2013; 34(1):3-6. PubMed ID: 23406927
[TBL] [Abstract][Full Text] [Related]
27. Patients perception of self-administrated medication in the treatment of hereditary angioedema.
Wang A; Fouche A; Craig TJ
Ann Allergy Asthma Immunol; 2015 Aug; 115(2):120-5. PubMed ID: 26118352
[TBL] [Abstract][Full Text] [Related]
28. Recent advances in management and treatment of hereditary angioedema.
Sardana N; Craig TJ
Pediatrics; 2011 Dec; 128(6):1173-80. PubMed ID: 22065270
[TBL] [Abstract][Full Text] [Related]
29. US Hereditary Angioedema Association Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency.
Zuraw BL; Banerji A; Bernstein JA; Busse PJ; Christiansen SC; Davis-Lorton M; Frank MM; Li HH; Lumry WR; Riedl M;
J Allergy Clin Immunol Pract; 2013; 1(5):458-67. PubMed ID: 24565617
[TBL] [Abstract][Full Text] [Related]
30. Update on treatment of hereditary angioedema.
Xu YY; Buyantseva LV; Agarwal NS; Olivieri K; Zhi YX; Craig TJ
Clin Exp Allergy; 2013 Apr; 43(4):395-405. PubMed ID: 23517035
[TBL] [Abstract][Full Text] [Related]
31. Recombinant human-C1 inhibitor is effective and safe for repeat hereditary angioedema attacks.
Li HH; Moldovan D; Bernstein JA; Reshef A; Porebski G; Stobiecki M; Baker J; Levy R; Relan A; Riedl M
J Allergy Clin Immunol Pract; 2015; 3(3):417-23. PubMed ID: 25680925
[TBL] [Abstract][Full Text] [Related]
32. Hereditary angioedema: a brief review of new developments.
Altman KA; Naimi DR
Curr Med Res Opin; 2014 May; 30(5):923-30. PubMed ID: 24432781
[TBL] [Abstract][Full Text] [Related]
33. The safety of treatments for angioedema with hereditary C1 inhibitor deficiency.
Zanichelli A; Wu MA; Andreoli A; Mansi M; Cicardi M
Expert Opin Drug Saf; 2015; 14(11):1725-36. PubMed ID: 26429506
[TBL] [Abstract][Full Text] [Related]
34. Update on therapeutic developments for hereditary angioedema.
Christiansen SC; Zuraw BL
Allergy Asthma Proc; 2009; 30(5):500-5. PubMed ID: 19843404
[TBL] [Abstract][Full Text] [Related]
35. Hereditary angioedema: current and emerging treatment options.
Levy JH; Freiberger DJ; Roback J
Anesth Analg; 2010 May; 110(5):1271-80. PubMed ID: 20418292
[TBL] [Abstract][Full Text] [Related]
36. Appraisal of danazol prophylaxis for hereditary angioedema.
Craig TJ
Allergy Asthma Proc; 2008; 29(3):225-31. PubMed ID: 18387221
[TBL] [Abstract][Full Text] [Related]
37. Current medical management of hereditary angioedema: results from a large survey of US physicians.
Riedl M; Gower RG; Chrvala CA
Ann Allergy Asthma Immunol; 2011 Apr; 106(4):316-322.e4. PubMed ID: 21457880
[TBL] [Abstract][Full Text] [Related]
38. Self-administration of intravenous C1-inhibitor therapy for hereditary angioedema and associated quality of life benefits.
Bygum A; Andersen KE; Mikkelsen CS
Eur J Dermatol; 2009; 19(2):147-51. PubMed ID: 19264579
[TBL] [Abstract][Full Text] [Related]
39. Hereditary angioedema in Greece: the first results of the greek hereditary angioedema registry.
Psarros F; Koutsostathis N; Farmaki E; Speletas MG; Germenis AE
Int Arch Allergy Immunol; 2014; 164(4):326-32. PubMed ID: 25277223
[TBL] [Abstract][Full Text] [Related]
40. Use of recombinant C1 inhibitor in patients with resistant or frequent attacks of hereditary or acquired angioedema.
Manson AL; Dempster J; Grigoriadou S; Buckland MS; Longhurst HJ
Eur J Dermatol; 2014; 24(1):28-34. PubMed ID: 24556385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
